Thalassemia major
Conditions
Interventions
Control group:conventional therapy
experimental group:Eltrabopag (1mg/kg) combined with conventional therapy
Sponsors
The First Affilited Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 2 to 18 years; 2. Gender: Male or female; 3. Thalassemia major; 4. HLA-matched related hematopoietic stem cell transplantation; 5. In good general condition, ECOG score less than 1;
Exclusion criteria
Exclusion criteria: 1. Severe infection uncontrolled before transplantation; Severe allergic on Antithymocyte globulin (anaphylactic shock or laryngeal edema); Cardiac dysfunction (ejection fraction less than 50%); Renal insufficiency (serum creainine more than 130umol/L); Hepatic dysfunction (total bilirubin more than 34umol/L, ALT, AST more than 2 times the upper limit of normal); 2. Previously history of allogeneic hematopoietic stem cell transplantation; 3. Other circumstances which do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet engraftment time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;2-year overall survival and disease-free survival; | — |
Countries
China
Contacts
Public Contact+86 Lai yongrong
The First Affilited Hospital of Guangxi Medical University
Outcome results
None listed